Avaglim
rosiglitazone / glimepiride
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Avaglim has been withdrawn for safety reasons following a decision by the European Commission.
This EPAR was last updated on 12/08/2011
Authorisation details
| Product details | |
|---|---|
| Name |
Avaglim
|
| Agency product number |
EMEA/H/C/000675
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
rosiglitazone / glimepiride
|
| Therapeutic area (MeSH) |
Diabetes Mellitus, Type 2
|
| Anatomical therapeutic chemical (ATC) code |
A10BD04
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
SmithKline Beecham Ltd
|
| Revision |
11
|
| Date of issue of marketing authorisation valid throughout the European Union |
27/06/2006
|
| Contact address | |
Product information
26/07/2011 Avaglim - EMEA/H/C/000675 - A20/0029
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Drugs used in diabetes
Therapeutic indication
Therapeutic indication
AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.